Welcome to our dedicated page for Progyny SEC filings (Ticker: PGNY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Progyny, Inc. filings document public-company reporting for its Nasdaq-listed common stock and its women's health and family building benefits business. Recent Form 8-K reports furnish quarterly and annual financial results, guidance updates, Regulation FD materials, supplemental earnings presentations, and other material-event disclosures.
The company's proxy materials cover annual meeting governance, director and executive compensation, equity award information, and related shareholder voting matters. Other filings address executive employment and compensatory arrangements, as well as a derivative-action settlement notice tied to historical non-employee director compensation practices.
Mark Livingston submitted a notice under Rule 144 reporting an intended sale of 279 shares of common stock tied to restricted stock vesting on 06/02/2026. The filing also lists a prior sale of 8,275 shares on 05/20/2026 for $211,012.50.
Progyny, Inc. executive vice president and general counsel Allison Swartz reported two transactions in company common stock on May 28, 2026. She completed an open-market sale of 2,398 shares at $25.46 per share under a pre-established Rule 10b5-1 trading plan. Separately, 1,352 shares were withheld to cover withholding taxes upon the vesting of restricted stock units, which is a non-market, compensation-related event. After these transactions, she directly owned 87,589 shares of Progyny common stock.
Cheryl Scott reports a proposed sale of Common stock of PGNY. The filing identifies 2,676 shares linked to a sale dated 06/01/2026 and notes a prior sale of 2,676 shares on 05/22/2026 for $66,177.48. The broker listed is Fidelity Brokerage Services LLC and an option grant date of 10/24/2019 is shown.
Progyny director Kevin K. Gordon reported an open-market sale and related share transfers. On 2026-05-27, he sold 5,500 shares of Progyny common stock at $24.99 per share, leaving 9,318 shares held directly. Separate restructuring transactions moved 2,526 shares from his direct ownership into the Kevin Gordon Revocable Declaration of Trust U/A/D 9/3/2013, which now holds 15,027 shares with Gordon serving as trustee.
PGNY filing of a Form 144 notifies the proposed sale of 2,398 shares of Common Stock by an affiliate on 05/28/2026. The entry lists the method as Restricted Stock Vesting and the purpose as Compensation. The excerpt also discloses prior sales by Allison C. Swartz: 2,199 shares on 03/02/2026, 4,657 shares on 03/03/2026, and 599 shares on 03/04/2026, with the corresponding proceeds reported in the table.
Progyny, Inc. held its 2026 Annual Meeting of Stockholders where shareholders approved changes to its charter and bylaws that remove several supermajority voting requirements. These amendments make it easier for holders of a simple majority of shares to approve certain actions and business combinations.
Stockholders also elected three Class I directors to serve until the 2029 annual meeting, ratified Ernst & Young LLP as independent auditor for the 2026 fiscal year, and approved on an advisory basis the compensation of named executive officers. Overall shareholder participation was high, with over 91% of eligible shares represented in person or by proxy.
Progyny, Inc. director Elizabeth D. Bierbower received equity-based compensation. She was granted 5,660 restricted stock units, each representing one share of common stock, and stock options covering 27,119 and 3,203 shares at an exercise price of $24.69. These awards vest on the earlier of May 21, 2027 or immediately before the company’s first annual stockholder meeting following the grant date, and the larger option grant replaces a $39,990 annual cash retainer for board and committee service.
Progyny, Inc. director Dean Lloyd H received new equity compensation consisting of common stock underlying restricted stock units and stock options. He was granted 6,792 shares of common stock underlying restricted stock units, bringing his direct common stock holdings to 26,519 shares.
He was also granted a stock option covering 28,203 shares of common stock at an exercise price of $24.69 per share, expiring on May 20, 2036. Both the restricted stock units and the option will vest on the earlier of May 21, 2027 or the calendar day immediately preceding Progyny’s first annual meeting of stockholders following the grant date, subject to his continued service.
Progyny, Inc. director Kevin K. Gordon reported equity awards and updated holdings. He received a grant of 6,792 shares of common stock in the form of restricted stock units (RSUs), each representing one share, at a stated price of $0.0000 per share. These RSUs vest on the earlier of May 21, 2027 or the calendar day immediately before Progyny’s first annual stockholders’ meeting following the grant date, subject to his continued service. Gordon also received a stock option for 30,373 shares of common stock at an exercise price of $24.6900 per share, vesting on the same schedule.
After these awards, he holds 14,818 shares of common stock directly, 12,501 shares indirectly through the Kevin Gordon Revocable Declaration of Trust where he serves as trustee, and 30,373 stock options scheduled to vest as described.